Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Myelodysplastic syndromes (MDS) occur when the cells that make blood cells are abnormal. There are limited treatment options for MDS. Researchers want to learn more through this natural history study so they can develop better treatments. Objective: To study the natural course of MDS and MDS/myeloproliferative neoplasms (MPN) and collect biological samples that can help researchers understand the disease. Eligibility: People with suspected or confirmed MDS or MDS/MPN. Healthy donors are also needed. They can be people who are scheduled to donate bone marrow at NIH for a relative, or they may be providing bone marrow in another study. Design: Participants will be screened with a medical history. Participants will have a physical exam. They will give blood and urine samples. They will discuss their symptoms, medications, and ability to perform their normal activities. They will complete surveys about how they are feeling. Participants will have a bone marrow biopsy. A needle will be inserted through a small cut. Bone marrow will be removed. A small piece of bone may be removed. Participants may have an optional skin biopsy. Participants may give optional saliva and stool samples. They may collect these samples at home and mail them to NIH. Participants may undergo optional apheresis. One or two needles or intravenous (IV) lines will be placed in their arm, neck, or groin veins. Blood will be removed. A machine will separate out the white cells. The rest of the blood will be returned to the participant. Participants will be contacted for follow-up once a year for up to 20 years. Healthy donors will have marrow collected for this study during their scheduled procedure with no follow-up.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podejrzenie lub potwierdzone rozpoznanie zespołu mielodysplastycznego lub pokrewnych chorób krwi
- •Osoby w dowolnym wieku i obu płci
- •Wcześniejsze leczenie dopuszczalne, można być w trakcie leczenia
- •Musi być lekarz (onkolog, hematolog lub internista) poza NIH, który będzie zajmować się Twoją opieką
- •Zdrowi dawcy: gotowość do oddania szpiku kostnego w zaplanowanym już terminie
- •Chęć udziału w badaniu i dostępność przez okres trwania badania
- •Możliwość zrozumienia i podpisania zgody (osoba lub rodzic/opiekun)
✗ Disqualifies
- •Niekontrolowana choroba zakaźna, problemy psychiatryczne lub inne stany utrudniające udział w badaniu
- •Dla zdrowych dawców: historia choroby nowotworowej krwi lub obecna choroba autoimmunologiczna
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Day
- Maximum age
- 120 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Danielle F Pinkiert, R.N.
Kathy L McGraw, Ph.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.